# US 2021/0260050 A1 · Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260050 A1
- Document ID: US20210260050A1
- Status: Published application
- Kind: A1
- Application number: 17/241,906
- Filed: 2021-04-27
- Published: 2021-08-26
- Earliest claimed: 2018-11-06
- Assignees: Beijing Innocare Pharma Tech Co., Ltd.
- Applicants: Beijing Innocare Pharma Tech Co., Ltd.
- Inventors: Xiangyang Chen; Zuopeng WANG; Liqin YU
- Web page: https://patentgrep.com/patent/US20210260050A1

## CPC

- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an amorphous solid dispersion comprises 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (Compound I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer. The present invention also relates to pharmaceutical compositions comprising the amorphous solid dispersion. The amorphous solid dispersion of the present invention is stable upon storage and provides a better dissolution rate and bioavailability when comparing with a crystalline form.

## Claims

### Claim 1

An amorphous solid dispersion comprises compound I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer,
wherein the polymer is selected from the group consisting of hydroxypropylmethylcellulose-acetate succinate (HPMC-AS), polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), polyvinylpyrrolidone (PVP), and hydroxypropylmethylcellulose (HPMC).

### Claim 2 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein the polymer is HPMC-AS or PVP-VA.

### Claim 3 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein compound I is 10-50% w/w of the dispersion.

### Claim 4 (depends on 3)

The amorphous solid dispersion according to claim 3, wherein compound I is 15-40% w/w of the dispersion.

### Claim 5 (depends on 1)

The amorphous solid dispersion according to claim 1 wherein the weight ratio of compound I to the polymer is in the range of from about 1:1 to 1:10.

### Claim 6 (depends on 1)

The amorphous solid dispersion according to claim 1, prepared by spray-drying or hot-melt extrusion.

### Claim 7 (depends on 1)

A pharmaceutical composition comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the amorphous solid dispersion according to claim 1.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, in a tablet form or a capsule form.

### Claim 9 (depends on 1)

A method for preparing the amorphous solid dispersion of claim 1, comprising the steps:
(a) dissolving compound I or a pharmaceutically acceptable salt thereof and the polymer in an organic solvent to form a solution; and
(b) spraying drying the solution to form the amorphous solid dispersion.
